focus -WSS

focus

author：hotspot 2025-10-02 21:00:44 - browse：8517

ESMO signage in Madrid. — At ESMO 2023, antibody-drug conjugates were featured prominently. Andrew Joseph/STAT

MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting, a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.

The conference opened to the news that Merck had signed one of the biggest licensing deals in industry history — worth up to $22 billion — to partner on three of the compounds from ADC specialist Daiichi Sankyo. GSK followed up with an ADC licensing announcement of its own (if a much smaller one). Multiple ADC studies were presented at the meeting’s top sessions. ADCs were, in short, the belle of the cancer research ball.

The thing is, ADCs are actually quite an old approach.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Readout Newsletter: Bristol, Sangamo, Gilead, and more

leisure time

WSS

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Key Senate panel to consider PBM, drug pricing reform package

Humans aren't the only ones with an imagination. Rats have it too

Key Senate panel to consider PBM, drug pricing reform package

Male and female sex labels in research insufficient, scientists say

President Biden's budget: Here's what you might have missed

focus

focus

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Inari Medical to buy amputation prevention company LimFlow

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Bristol, Sangamo, Gilead, and more

In Memoriam: Notable people who died in 2023

Gene therapy’s promise and the high cost of hope

Virginia high school admissions case could be legal follow

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

leisure time

Why scientists need input from humanists on sensitive research

Humans aren't the only ones with an imagination. Rats have it too

President Biden's budget: Here's what you might have missed

Inari Medical to buy amputation prevention company LimFlow

Travis Kelce and the trap of celebrity vaccine endorsements

Life sciences investors close nearly $6 billion in new funds

leisure time

explore

explore

Wikipedia